CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia
| Autor: | Kamonporn Kotemul, Watchara Kasinrerk, Nuchjira Takheaw |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 1, Pp 96-107 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2692-3114 59984244 |
| DOI: | 10.37349/etat.2024.00207 |
| Popis: | Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is an aggressive hematologic malignancy. T-ALL patients who are treated with chemotherapeutic drugs frequently relapse and become drug resistant. Therefore, antibody-based therapy is promising for T-ALL treatment. To successfully develop an antibody-based therapy for T-ALL, antibodies that induce death in malignant T cells but not in nonmalignant T cells are required to avoid the induction of secondary T-cell immunodeficiency. In this review, CD99 tumor associated antigen, which is highly expressed on malignant T cells and lowly expressed on nonmalignant T cells, is proposed to be a potential target for antibody therapy of T-ALL. Since certain clones of anti-CD99 mAbs induce apoptosis only in malignant T cells, these anti-CD99 mAbs might be a promising antibody drug for the treatment of T-ALL with high efficiency and low adverse effects. Moreover, over the past 25 years, many clones of anti-CD99 mAbs have been studied for their direct effects on T-ALL. These outcomes are gathered here. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|